Legal & General Group’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,714
| Closed | -$48.6K | – | 3367 |
|
|
2025
Q4 | $48.6K | Buy |
3,714
+515
| +16% | +$6.15K | ﹤0.01% | 2732 |
|
|
2025
Q3 | $23.3K | Sell |
3,199
-545
| -15% | -$3.69K | ﹤0.01% | 2980 |
|
|
2025
Q2 | $20.1K | Sell |
3,744
-27,674
| -88% | -$134K | ﹤0.01% | 3004 |
|
|
2025
Q1 | $168K | Hold |
31,418
| – | – | ﹤0.01% | 2629 |
|
|
2024
Q4 | $281K | Buy |
31,418
+2,222
| +8% | +$23.6K | ﹤0.01% | 2618 |
|
|
2024
Q3 | $321K | Buy |
29,196
+20,142
| +222% | +$224K | ﹤0.01% | 2596 |
|
|
2024
Q2 | $82.4K | Buy |
9,054
+3,996
| +79% | +$39K | ﹤0.01% | 2740 |
|
|
2024
Q1 | $71.2K | Buy |
5,058
+1,566
| +45% | +$19.5K | ﹤0.01% | 2755 |
|
|
2023
Q4 | $26.8K | Buy |
3,492
+894
| +34% | +$4.94K | ﹤0.01% | 2924 |
|
|
2023
Q3 | $19.4K | Sell |
2,598
-421
| -14% | -$3.59K | ﹤0.01% | 3042 |
|
|
2023
Q2 | $25.1K | Buy |
+3,019
| New | +$34.8K | ﹤0.01% | 3016 |
|
|
2021
Q2 | – | Sell |
-343
| Closed | -$6K | – | 3491 |
|
|
2021
Q1 | $6K | Hold |
343
| – | – | ﹤0.01% | 3458 |
|
|
2020
Q4 | $4K | Hold |
343
| – | – | ﹤0.01% | 3441 |
|
|
2020
Q3 | $13K | Sell |
343
-112
| -25% | -$4.44K | ﹤0.01% | 3117 |
|
|
2020
Q2 | $18K | Buy |
+455
| New | +$16.2K | ﹤0.01% | 3099 |
|
Legal & General Group's ATXS Position: Q1 2026 in Review
Legal & General Group sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 3,714 shares — an estimated $48.6K sold.
Legal & General Group first reported a position in ATXS in Q2 2020 and held it in 15 quarters. The position peaked at $321K in Q3 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Legal & General Group reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Legal & General Group sold 3,714 Astria Therapeutics shares in Q1 2026, an estimated $48.6K.
- Legal & General Group first reported a position in Astria Therapeutics in Q2 2020 and held it in 15 quarters.
- Legal & General Group's Astria Therapeutics position peaked at $321K in Q3 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.